Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analys

StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Adaptimmune Therapeutics Trading Up 14.9 % Shares of NASDAQ:ADAP opened at $0.79 on Friday. Adaptimmune Therapeutics has a 1 year low of […]

Related Keywords

United Kingdom , United States , America , , Baillie Gifford Co , Asset Management , Adaptimmune Therapeutics Company Profile , Nasdaq , America Corp , Long Focus Capital Management , Adaptimmune Therapeutics , Free Report , Get Free Report , Focus Capital Management , Rock Springs Capital Management , Springs Capital Management , Adaptimmune Therapeutics Daily , Nasdaq Adap , Hadap , Medical , Initiated Coverage , Stocknews Com ,